Skip to main content

Discontinuation Notice: Levemir Products to be Discontinued from January 2024

Medically reviewed by Judith Stewart, BPharm. Last updated on Jan 30, 2024.

November 8, 2024 -- Due to global manufacturing constraints, formulary losses impacting patient access, and the availability of alternative options, Novo Nordisk will be discontinuing Levemir® in the U.S.

The company will continue to provide Levemir® FlexPen® and Levemir® vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected.

  • Mid-January 2024: Supply disruptions of Levemir® FlexPen®
  • April 1, 2024: Discontinuation of Levemir® FlexPen®
  • December 31, 2024: Full brand discontinuation, including Levemir® vial

Novo Nordisk's top priority is always the health and safety of the patients that use our products. The company made this decision after careful consideration, and is confident that patients will be able to access alternative treatments in the U.S.

The company recommends that healthcare providers talk to their patients about alternative treatment options in advance of this supply disruption and discontinuation to ensure continuity of care.

Source: Novo Nordisk

Reference: Levemir Product Information

Posted November 2023

Read this next

Irregular Sleep Duration Tied to Increased Risk for Developing Diabetes

FRIDAY, July 19, 2024 -- Irregular sleep duration is associated with elevated diabetes risk, according to a study published online July 17 in Diabetes Care. Sina Kianersi, Ph.D...

Accelerated Progression to T1D During Pandemic Seen for Presymptomatic Youth

THURSDAY, July 18, 2024 -- For youth with presymptomatic type 1 diabetes, the COVID-19 pandemic was associated with accelerated progression to clinical disease, especially among...

Aging Into Medicare Tied to Higher Drug Costs for People With Diabetes

WEDNESDAY, July 17, 2024 -- As people with diabetes age into Medicare, they face increased quarterly out-of-pocket costs for medication, according to a study published online July...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.